Aft Pharmaceuticals Ltd
AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, … Read more
Aft Pharmaceuticals Ltd (AFP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.006x
Based on the latest financial reports, Aft Pharmaceuticals Ltd (AFP) has a cash flow conversion efficiency ratio of -0.006x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-609.04K) by net assets (AU$97.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aft Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Aft Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aft Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aft Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Senzime AB (publ)
OTCGREY:SNZZF
|
-0.068x |
|
Paramount Communications Limited
NSE:PARACABLES
|
-0.075x |
|
STPCF
OTCGREY:STPCF
|
N/A |
|
West Wits Mining Limited
PINK:WMWWF
|
0.000x |
|
Verde Resources Inc
OTCQB:VRDR
|
-0.021x |
|
Soechi Lines Tbk
JK:SOCI
|
0.031x |
|
Famon Awal Bros Sedaya
JK:PRAY
|
0.026x |
|
Compagnie Du Mont-Blanc
PA:MLCMB
|
0.078x |
Annual Cash Flow Conversion Efficiency for Aft Pharmaceuticals Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Aft Pharmaceuticals Ltd from 2013 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | AU$97.08 Million | AU$13.18 Million | 0.136x | -58.71% |
| 2024-03-31 | AU$87.80 Million | AU$28.86 Million | 0.329x | +107.12% |
| 2023-03-31 | AU$73.27 Million | AU$11.63 Million | 0.159x | -30.12% |
| 2022-03-31 | AU$62.31 Million | AU$14.15 Million | 0.227x | +1008.03% |
| 2021-03-31 | AU$36.59 Million | AU$750.00K | 0.020x | -97.62% |
| 2020-03-31 | AU$17.25 Million | AU$14.88 Million | 0.862x | +311.40% |
| 2019-03-31 | AU$5.09 Million | AU$1.07 Million | 0.210x | +116.79% |
| 2018-03-31 | AU$7.34 Million | AU$-9.17 Million | -1.249x | -27.53% |
| 2017-03-31 | AU$19.47 Million | AU$-19.06 Million | -0.979x | -98.24% |
| 2016-03-31 | AU$28.23 Million | AU$-13.94 Million | -0.494x | +92.38% |
| 2015-03-31 | AU$2.02 Million | AU$-13.11 Million | -6.484x | -30046.20% |
| 2014-03-31 | AU$3.05 Million | AU$66.00K | 0.022x | +102.37% |
| 2013-03-31 | AU$4.34 Million | AU$-3.97 Million | -0.915x | -- |